stockrowJohnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) Revenue
Johnson & Johnson's revenue for fiscal 2025 was $94.2B, up 6.05% from $88.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $99.3B. Over the past ten years it has ranged from $70.1B (fiscal 2015) to $94.2B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Johnson & Johnson ranks 1st of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $94.2B | 6.05% |
| FY2024 | $88.8B | 4.30% |
| FY2023 | $85.2B | 6.46% |
| FY2022 | $80.0B | 1.59% |
| FY2021 | $78.7B | (4.65%) |
| FY2020 | $82.6B | 0.64% |
| FY2019 | $82.1B | 0.59% |
| FY2018 | $81.6B | 6.71% |
| FY2017 | $76.5B | 6.34% |
| FY2016 | $71.9B | 2.59% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $25.4B | 0.35% |
| Jun 2026 | $25.3B | 5.19% |
| Mar 2026 | $24.1B | (2.04%) |
| Dec 2025 | $24.6B | 2.38% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| JNJ Johnson & Johnson | $99.3B |
| LLY Eli Lilly and Company compare | $86.5B |
| MRK Merck & Co., Inc. compare | $67.4B |
| ABBV AbbVie Inc. compare | $66.0B |
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC compare | $62.4B |
| NVS Novartis AG compare | $57.4B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on JNJ
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement